Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy
Open Access
- 15 May 2020
- journal article
- research article
- Published by Elsevier BV in The Lancet Respiratory Medicine
- Vol. 8 (8), 807-815
- https://doi.org/10.1016/s2213-2600(20)30225-3
Abstract
No abstract availableThis publication has 110 references indexed in Scilit:
- Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trialsRespiratory Research, 2013
- Genetic partitioning of interleukin‐6 signalling in mice dissociates Stat3 from Smad3‐mediated lung fibrosisEMBO Molecular Medicine, 2012
- Regulation of Transforming Growth Factor-β1–driven Lung Fibrosis by Galectin-3American Journal of Respiratory and Critical Care Medicine, 2012
- Viral Infection in Acute Exacerbation of Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Efficacy and Safety of Sirolimus in LymphangioleiomyomatosisThe New England Journal of Medicine, 2011
- Functional Disability 5 Years after Acute Respiratory Distress SyndromeThe New England Journal of Medicine, 2011
- A novel, orally active LPA1 receptor antagonist inhibits lung fibrosis in the mouse bleomycin modelBritish Journal of Pharmacology, 2010
- Modulation of Hepatic Fibrosis by c-Jun-N-Terminal Kinase InhibitionGastroenterology, 2010
- Role of Integrin αvβ6 in Acute Lung Injury Induced byPseudomonas aeruginosaInfection and Immunity, 2008
- Interleukin-1β Causes Acute Lung Injury via αvβ5 and αvβ6 Integrin–Dependent MechanismsCirculation Research, 2008